EP0867197A2 - Implantable drug delivery device - Google Patents

Implantable drug delivery device Download PDF

Info

Publication number
EP0867197A2
EP0867197A2 EP98810214A EP98810214A EP0867197A2 EP 0867197 A2 EP0867197 A2 EP 0867197A2 EP 98810214 A EP98810214 A EP 98810214A EP 98810214 A EP98810214 A EP 98810214A EP 0867197 A2 EP0867197 A2 EP 0867197A2
Authority
EP
European Patent Office
Prior art keywords
port
opening
skin
port body
human
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP98810214A
Other languages
German (de)
French (fr)
Other versions
EP0867197B1 (en
EP0867197A3 (en
Inventor
G.E. Prof. Dr. Bestetti
Thomas Frei
Andreas Reinmann
Daniel Piller
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tecpharma Licensing AG
Original Assignee
Disetronic Licensing AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Disetronic Licensing AG filed Critical Disetronic Licensing AG
Publication of EP0867197A2 publication Critical patent/EP0867197A2/en
Publication of EP0867197A3 publication Critical patent/EP0867197A3/en
Application granted granted Critical
Publication of EP0867197B1 publication Critical patent/EP0867197B1/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M39/00—Tubes, tube connectors, tube couplings, valves, access sites or the like, specially adapted for medical use
    • A61M39/02—Access sites
    • A61M39/0247—Semi-permanent or permanent transcutaneous or percutaneous access sites to the inside of the body
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M39/00—Tubes, tube connectors, tube couplings, valves, access sites or the like, specially adapted for medical use
    • A61M39/02—Access sites
    • A61M39/0247—Semi-permanent or permanent transcutaneous or percutaneous access sites to the inside of the body
    • A61M2039/0261—Means for anchoring port to the body, or ports having a special shape or being made of a specific material to allow easy implantation/integration in the body
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M39/00—Tubes, tube connectors, tube couplings, valves, access sites or the like, specially adapted for medical use
    • A61M39/02—Access sites
    • A61M39/0247—Semi-permanent or permanent transcutaneous or percutaneous access sites to the inside of the body
    • A61M2039/0282—Semi-permanent or permanent transcutaneous or percutaneous access sites to the inside of the body with implanted tubes connected to the port
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M39/00—Tubes, tube connectors, tube couplings, valves, access sites or the like, specially adapted for medical use
    • A61M39/02—Access sites
    • A61M39/0247—Semi-permanent or permanent transcutaneous or percutaneous access sites to the inside of the body
    • A61M2039/0288—Semi-permanent or permanent transcutaneous or percutaneous access sites to the inside of the body protectors, caps or covers therefor

Definitions

  • the invention relates to an implantable Port body for the administration of drugs according to the Preamble of claim 1.
  • a subcutaneously implantable port body is known from US-A-5 306 255.
  • a subcutaneous port body lies completely under the skin and usually remains in the human body for several months or even years.
  • the port chamber is located inside the port body.
  • the port chamber which is completely in the human or animal body, is sealed on the skin side by a piercing membrane made of plastic, while a catheter is attached to the inside of the body, which leads to the place of distribution for medicinal products.
  • the skin and membrane are pierced with a needle of an infusion set. This creates a continuous drug channel that extends from the infusion set to the point of delivery.
  • a cylindrical, percutaneously implantable port body is known from patent specification EP-B-0 302 076.
  • the percutaneous port body is not completely implanted in a human body, but rather is attached to the tissue in such a way that at least a certain area of the port body is not covered by skin.
  • a second opening of the port body is located opposite the first opening, in the area of the port body completely surrounded by tissue.
  • a catheter is connected to this opening, the end of which is located at the location within the body to which the medicament is to be transported.
  • the port body consists of two screwed metal parts. Inside the port body, the port chamber, there is a pierceable membrane that separates the two openings.
  • the port body is additionally anchored in the tissue by means of a base plate.
  • the disadvantages of the subcutaneous port are that one neither replace the catheter nor clean it mechanically can without explanting the port.
  • Another disadvantage is that the skin is always in the same place is punctured. This is painful in the short term and leads to perforation of the skin and membrane in the long term.
  • the disadvantages of the percutaneous port mentioned exist in being very heavy and visible from the outside Area is very large.
  • the radial grooves are designed and dimensioned to create sharp edges and corners. On these places is an optimal waxing of the Tissue cells and adequate surface cleaning not possible.
  • the invention seeks to remedy this.
  • the invention is based on the task of creating an inexpensive port develop, whose body-shaped housing a coherent surface and flowing transitions having.
  • the port should preferably be injection molded are manufactured and are biocompatible.
  • the skin has to can cling tightly to the port wall.
  • the Skin waxing depth should be as uniform as possible and can be regulated by the port.
  • the shape of the anchor must be designed so that in the event of a tilting moment no edges or other parts of the anchor from the Body of the patient can protrude.
  • the invention solves the problem with one Port body, which has the features of claim 1.
  • the advantages achieved by the invention are in essential to see that the port body is cheaper to manufacture while in use can be better cleaned by the design of the External surface is held better by the body and in case moment of tilting the skin over the anchoring surfaces rolls off.
  • the choice of material, the shape and the Surface structure of the port body allow a longer implantation time.
  • inside inside the human or animal body and outside outside the human or animal body.
  • the Divide port body 1 into two main elements: one hollow cylindrical shaft 14 and an arranged thereon radial anchor plate 13.
  • the port body 1 has two opposite openings 31a, 32 on.
  • the outward opening 31a corresponds to the inside diameter of the cylindrical Port body 1.
  • This opening 31a can through a lid 22, in the center of which there is a smaller opening 31b is reduced. Through this little The remaining opening 31b can be inserted into an infusion tube Interior of the port body can be pushed.
  • the second, against internal opening 32 is used to arrange a Catheter 2, which the drug to be administered transported to the desired location inside the body.
  • the inner wall 7 of the cylindrical port body 1 is in the Area of the cover 22 with bayonet cams 6 with integrated locking groove provided so that the lid 22, which is provided with corresponding counter elements, can be attached to the port body.
  • the hollow cylindrical shaft 14 and the anchoring plate 13 become one, biologically compatible Injection molded plastic part. Between the two openings 31b, 32 there is an elastic, self-closing Membrane 21, which through the hollow cylindrical shaft 14 formed chamber 20 fills and seals.
  • the cylindrical port body 14 is divided into two areas divided, an outer shaft portion 15 and an inward anchoring part 16. Between the two areas 15, 16 is a radial, protruding port rib 11 arranged.
  • the shaft part 15 consists of an inert material from smooth surface structure. It ends with the outside against the outside opening 31a and against the Anchoring part 16 with the protruding port rib 11. In the skin cannot grow in this area. From the outside you can see the shaft part 15 in the implanted state clean up to the port rib 11.
  • the anchoring part 16 consists of the port rib 11, one from the anchoring part 16 projecting anchoring rib 12 and the anchor plate 13. Both the port rib 11, such the anchoring rib 12 also have a peripheral one Rib margin lla, 12a.
  • the port rib 11 and the Anchoring rib 12 form an intermediate one channel-shaped radial pocket 10 by the distance between the two peripheral rib edges 11a, 12a essential is narrower than the cross-sectional diameter of the radial Bag 10 itself.
  • Tissue cells in the channel-shaped, radial pocket 10 wax in.
  • the anchoring rib 12 can be part of the anchoring plate 13 or independent of this between the port rib 11 and the anchor plate 13 are arranged.
  • the anchoring part 16 is made of a bioactive material coated and has a rough surface structure. Thereby can spread tissue in the pocket 10 and Tissue cells can adhere to the rough surface hold tight.
  • tissue When tissue grows into the radial pocket 10 the tissue is wedged in the radial pocket 10 and ensures a positive connection between the fabric and the Radial pocket surface 10.
  • the anchor plate 13 is radial around the Anchoring part 16 of the hollow cylindrical shaft 14 arranged.
  • the anchor plate 13 has one Skin surface peripherally sloping shape, which on reminded a plate.
  • the sloping shape causes the skin is affected by a tilting moment Port body 1 rolls over the anchor plate 13 and not from the edge 17 can be pierced.
  • Bores 24 are made in the anchoring plate 13, which be overgrown by the surrounding tissue and thus can offer optimal support.
  • the cover 22 preferably made in a skin-like color because this surface is visible to the outside.
  • the whole port body can also have a skin-like color getting produced.

Abstract

An implantable cylindrical device (1) for connecting a tube outside the human or animal body, to a tube (2) inside, has an associated anchoring plate (13) located around it, which falls off towards the skin at the periphery The device pref. consists of plastic.

Description

Die Erfindung bezieht sich auf einen implantierbaren Portkörper zur Verabreichung von Arzneimittel gemäss dem Oberbegriff des Anspruchs 1.The invention relates to an implantable Port body for the administration of drugs according to the Preamble of claim 1.

Aus der Patentschrift US-A-5 306 255 ist ein subcutan implantierbarer Portkörper bekannt. Ein subcutaner Portkörper liegt vollkommen unter der Haut und verbleibt normalerweise mehrere Monate oder sogar Jahre im menschlichen Körper. Im Inneren des Portkörpers befindet sich die Portkammer. Die sich vollständig im menschlichen oder tierischen Körper befindende Portkammer wird hautseitig durch eine Durchstechmembran aus Kunststoff abgeschlossen, während gegen das Körperinnere ein Katheter befestigt ist, welcher zum Ausschüttungsort für Arzneimittel führt. Zur Arzneimittelverabreichung werden Haut und Membrane mit einer Nadel eines Infusionssets durchstochen. Dadurch entsteht ein durchgängiger Arzneimittelkanal, welcher vom Infusionsset bis zum Ausschüttungsort reicht.
Aus der Patentschrift EP-B-0 302 076 ist ein zylindrischer, percutan implantierbarer Portkörper bekannt. Im Gegensatz zum subcutanen Portkörper wird der percutane Portkörper nicht vollständig in einen menschlichen Körper implantiert, sondern derart im Gewebe befestigt, dass zumindest eine bestimmte Fläche des Portkörpers nicht von Haut überdeckt wird. Im Zentrum dieser Fläche befindet sich eine erste Öffnung. Eine zweite Öffnung des Portkörpers befindet sich gegenüber der ersten Öffnung, im vollständig von Gewebe umgebenen Bereich des Portkörpers. An dieser Öffnung ist ein Katheter angeschlossen, dessen Ende sich an demjenigen Ort innerhalb des Körpers befindet, an den das Arzneimittel transportiert werden soll. Der Portkörper besteht aus zwei ineinandergeschraubten Metallteilen. Im Inneren des Portkörpers, der Portkammer, ist eine durchstechbare Membran angeordnet, welche die beiden Öffnungen trennt. Am Aussenmantel des Portkörpers sind mehrere radiale Rillen, zur seitlichen Verankerung des Ports im subcutanen Hautgewebe angeordnet, wobei sich die äusserste Rille direkt unter der Hautoberfläche befindet. Im Gewebe wird der Portkörper zusätzlich mittels einer Grundplatte verankert.A subcutaneously implantable port body is known from US-A-5 306 255. A subcutaneous port body lies completely under the skin and usually remains in the human body for several months or even years. The port chamber is located inside the port body. The port chamber, which is completely in the human or animal body, is sealed on the skin side by a piercing membrane made of plastic, while a catheter is attached to the inside of the body, which leads to the place of distribution for medicinal products. For drug administration, the skin and membrane are pierced with a needle of an infusion set. This creates a continuous drug channel that extends from the infusion set to the point of delivery.
A cylindrical, percutaneously implantable port body is known from patent specification EP-B-0 302 076. In contrast to the subcutaneous port body, the percutaneous port body is not completely implanted in a human body, but rather is attached to the tissue in such a way that at least a certain area of the port body is not covered by skin. There is a first opening in the center of this area. A second opening of the port body is located opposite the first opening, in the area of the port body completely surrounded by tissue. A catheter is connected to this opening, the end of which is located at the location within the body to which the medicament is to be transported. The port body consists of two screwed metal parts. Inside the port body, the port chamber, there is a pierceable membrane that separates the two openings. There are several radial grooves on the outer jacket of the port body for anchoring the port in the subcutaneous skin tissue, the outermost groove being located directly under the skin surface. The port body is additionally anchored in the tissue by means of a base plate.

Die Nachteile des subcutanen Ports bestehen darin, dass man den Katheter weder auswechseln, noch mechanisch reinigen kann, ohne den Port zu explantieren. Ein weiterer Nachteil besteht darin, dass die Haut immer an der gleichen Stelle durchstochen wird. Das ist kurzfristig schmerzhaft und führt längerfristig zur Perforation von Haut und Membran. Die Nachteile beim erwähnten percutanen Port bestehen darin, dass er sehr schwer und die von aussen sichtbare Fläche sehr gross ist. Zudem ist der aus Metall gefertigte Portkörper auch farblich sehr auffällig. Im montierten Zustand befindet sich ein Luftspalt zwischen der Grundplatte und dem Portkörper, welcher schwierig zu reinigen und zu sterilisieren ist. Hier besteht die Gefahr einer Infektion. Die radialen Rillen sind so angelegt und dimensioniert, dass scharfe Kanten und Ecken entstehen. An diesen Stellen ist ein optimales Einwachsen der Gewebezellen und eine ausreichende Reinigung der Oberfläche nicht möglich. Da keine geometrische Trennlinie zwischen der Hautoberfläche und der obersten Rille vorhanden ist, besteht die Gefahr, dass Körperschweiss oder Schmutz von aussen direkt in die Rillen gelangen. Es kommt im Extremfall zu einer Infektion und der Port muss explantiert werden. Ein weiterer Nachteil besteht darin, dass beim erwähnten Port die Einzelteile aus Vollmaterial in spannender Bearbeitung hergestellt werden müssen. Daher sind die Herstellkosten entsprechend hoch und jegliche Massnahme zur Gewichtsreduktion mit einem Mehraufwand verbunden. Bei den bisherigen Verankerungen besteht weiterhin die Gefahr, dass Teile der Verankerung, durch Einwirkung eines Kippmoments, aus der Haut ragen können.The disadvantages of the subcutaneous port are that one neither replace the catheter nor clean it mechanically can without explanting the port. Another disadvantage is that the skin is always in the same place is punctured. This is painful in the short term and leads to perforation of the skin and membrane in the long term. The disadvantages of the percutaneous port mentioned exist in being very heavy and visible from the outside Area is very large. In addition, the is made of metal Port body also very striking in color. In the assembled There is an air gap between the condition Base plate and the port body, which is difficult to is to be cleaned and sterilized. There is a danger here an infection. The radial grooves are designed and dimensioned to create sharp edges and corners. On these places is an optimal waxing of the Tissue cells and adequate surface cleaning not possible. Because there is no geometric dividing line between the skin surface and the top groove is present, there is a risk of body sweat or dirt from get directly into the grooves on the outside. It comes in Extreme case of infection and the port must be explanted will. Another disadvantage is that the Port mentioned the individual parts in solid material exciting machining must be produced. Therefore the manufacturing costs are correspondingly high and any Weight loss measure with additional effort connected. With the previous anchorages continue to run the risk of parts of anchoring Exposure to a tilting moment that may protrude from the skin.

Hier will die Erfindung Abhilfe verschaffen. Der Erfindung liegt die Aufgabe zugrunde, einen kostengünstigen Port zu entwickeln, dessen körpergerecht geformtes Gehäuse eine zusammenhängende Mantelfläche und fliessende Übergänge aufweist. Der Port soll vorzugsweise im Spritzgussverfahren hergestellt werden und biokompatibel sein. Die Haut muss sich fest an die Portwand klammern können. Die Einwachstiefe der Haut soll möglichst gleichmässig sein und vom Port reguliert werden können. Die Form der Verankerung muss so konzipiert werden, dass im Falle eines Kippmoments keine Kanten oder andere Teile der Verankerung aus dem Körper des Patienten ragen können.The invention seeks to remedy this. The invention is based on the task of creating an inexpensive port develop, whose body-shaped housing a coherent surface and flowing transitions having. The port should preferably be injection molded are manufactured and are biocompatible. The skin has to can cling tightly to the port wall. The Skin waxing depth should be as uniform as possible and can be regulated by the port. The shape of the anchor must be designed so that in the event of a tilting moment no edges or other parts of the anchor from the Body of the patient can protrude.

Die Erfindung löst die gestellte Aufgabe mit einem Portkörper, welcher die Merkmale des Anspruchs 1 aufweist.The invention solves the problem with one Port body, which has the features of claim 1.

Die durch die Erfindung erreichten Vorteile sind im wesentlichen darin zu sehen, dass der Portkörper kostengünstiger herzustellen ist, während dem Gebrauch besser gereinigt werden kann, durch die Ausgestaltung der Aussenfläche vom Körper besser gehalten wird und im Falle eines Kippmoments die Haut über die Verankerungsflächen abrollt. Die Wahl des Werkstoffes, die Form und die Oberflächenstruktur des Portkörpers ermöglichen eine längere Implantationszeit.The advantages achieved by the invention are in essential to see that the port body is cheaper to manufacture while in use can be better cleaned by the design of the External surface is held better by the body and in case moment of tilting the skin over the anchoring surfaces rolls off. The choice of material, the shape and the Surface structure of the port body allow a longer implantation time.

Ein bevorzugtes Ausführungsbeispiel der Erfindung ist in den Figuren dargestellt.A preferred embodiment of the invention is in shown the figures.

Es zeigen:

  • Fig. 1 einen erfindungsgemässen Portkörper im Querschnitt
  • Fig. 2 Einen erfindungsgemässen percutanen Portkörper, im menschlichen oder tierischen Körper angeordnet
    • Show it:
  • Fig. 1 shows a port body according to the invention in cross section
  • 2 shows a percutaneous port body according to the invention, arranged in the human or animal body

    • Im folgenden bedeuten die Begriffe innen = innerhalb des menschlichen oder tierischen Körpers und aussen = ausserhalb des menschlichen oder tierischen Körpers.In the following, the terms inside = inside the human or animal body and outside outside the human or animal body.

    Wie in den Fig. 1 und 2 dargestellt, lässt sich der Portkörper 1 in zwei Hauptelemente einteilen: einen hohlzylindrischen Schaft 14 und einen daran angeordneten radialen Verankerungsteller 13.As shown in FIGS. 1 and 2, the Divide port body 1 into two main elements: one hollow cylindrical shaft 14 and an arranged thereon radial anchor plate 13.

    Der Portkörper 1 weist zwei gegenüberliegende Öffnungen 31a,32 auf. Die gegen aussen liegende Öffnung 31a entspricht dem Innendurchmesser des zylindrischen Portkörpers 1. Diese Öffnung 31a kann durch einen Deckel 22, in dessen Zentrum sich eine kleinere Öffnung 31b befindet, verkleinert werden. Durch diese kleine, verbleibende Öffnung 31b kann ein Infusionsschlauch ins Innere des Portkörpers geschoben werden. Die zweite, gegen innen liegende Öffnung 32 dient zur Anordnung eines Katheters 2, welcher das zu verabreichende Arzneimittel an den gewünschten Ort im Körperinnern transportiert.The port body 1 has two opposite openings 31a, 32 on. The outward opening 31a corresponds to the inside diameter of the cylindrical Port body 1. This opening 31a can through a lid 22, in the center of which there is a smaller opening 31b is reduced. Through this little The remaining opening 31b can be inserted into an infusion tube Interior of the port body can be pushed. The second, against internal opening 32 is used to arrange a Catheter 2, which the drug to be administered transported to the desired location inside the body.

    Die Innenwandung 7 des zylindrischen Portkörpers 1 ist im Bereich des Deckels 22 mit Bajonettnocken 6 mit integrierter Verriegelungsnute versehen, so dass der Deckel 22, welcher mit entsprechenden Gegenelementen versehen ist, am Portkörper befestigt werden kann.The inner wall 7 of the cylindrical port body 1 is in the Area of the cover 22 with bayonet cams 6 with integrated locking groove provided so that the lid 22, which is provided with corresponding counter elements, can be attached to the port body.

    Der hohlzylindrische Schaft 14 und der Verankerungsteller 13 werden aus einem einzigen, biologisch verträglichen Kunststoffteil gespritzt. Zwischen den beiden Öffnungen 31b,32 befindet sich eine elastische, selbstschliessende Membran 21, welche die durch den hohlzylindrischen Schaft 14 gebildete Kammer 20 ausfüllt und abdichtet.The hollow cylindrical shaft 14 and the anchoring plate 13 become one, biologically compatible Injection molded plastic part. Between the two openings 31b, 32 there is an elastic, self-closing Membrane 21, which through the hollow cylindrical shaft 14 formed chamber 20 fills and seals.

    Der zylindrische Portkörper 14 wird in zwei Bereiche aufgeteilt, einen gegen aussen liegenden Schaftteil 15 und einen gegen innen liegenden Verankerungsteil 16. Zwischen den beiden Bereichen 15,16 ist eine radial verlaufende, vorstehende Portrippe 11 angeordnet.The cylindrical port body 14 is divided into two areas divided, an outer shaft portion 15 and an inward anchoring part 16. Between the two areas 15, 16 is a radial, protruding port rib 11 arranged.

    Der Schaftteil 15 besteht aus einem inerten Material von glatter Oberflächenstruktur. Er endet gegen aussen mit der gegen aussen liegenden Öffnung 31a und gegen den Verankerungsteil 16 mit der vorstehenden Portrippe 11. In diesem Bereich kann die Haut nicht anwachsen. Von aussen kann man den Schaftteil 15 im implantierten Zustand reinigen bis zur Portrippe 11.The shaft part 15 consists of an inert material from smooth surface structure. It ends with the outside against the outside opening 31a and against the Anchoring part 16 with the protruding port rib 11. In the skin cannot grow in this area. From the outside you can see the shaft part 15 in the implanted state clean up to the port rib 11.

    Der Verankerungsteil 16 besteht aus der Portrippe 11, einer vom Verankerungsteil 16 abstehende Verankerungsrippe 12 und dem Verankerungsteller 13. Sowohl die Portrippe 11, wie auch die Verankerungsrippe 12 weisen einen peripheren Rippenrand lla,12a auf. Die Portrippe 11 und die Verankerungsrippe 12 bilden eine dazwischenliegende kanalförmige, radiale Tasche 10, indem der Abstand zwischen den beiden peripheren Rippenrändern lla,12a wesentlich enger ist, als der Querschnittdurchmesser der radialen Tasche 10 selbst. Durch den zwischen den beiden Rippenrändern lla,12a gebildeten Abstand können Gewebezellen in die kanalförmige, radiale Tasche 10 einwachsen.The anchoring part 16 consists of the port rib 11, one from the anchoring part 16 projecting anchoring rib 12 and the anchor plate 13. Both the port rib 11, such the anchoring rib 12 also have a peripheral one Rib margin lla, 12a. The port rib 11 and the Anchoring rib 12 form an intermediate one channel-shaped radial pocket 10 by the distance between the two peripheral rib edges 11a, 12a essential is narrower than the cross-sectional diameter of the radial Bag 10 itself. By the between the two Rib edges lla, 12a formed distance Tissue cells in the channel-shaped, radial pocket 10 wax in.

    Die Verankerungsrippe 12 kann Teil des Verankerungstellers 13 sein oder unabhängig von diesem zwischen der Portrippe 11 und dem Verankerungsteller 13 angeordnet werden.The anchoring rib 12 can be part of the anchoring plate 13 or independent of this between the port rib 11 and the anchor plate 13 are arranged.

    Der Verankerungsteil 16 ist mit einem bioaktiven Material beschichtet und hat eine rauhe Oberflächenstruktur. Dadurch kann sich Gewebe in der Tasche 10 ausbreiten und Gewebezellen können sich an der rauhen Oberfläche festhalten.The anchoring part 16 is made of a bioactive material coated and has a rough surface structure. Thereby can spread tissue in the pocket 10 and Tissue cells can adhere to the rough surface hold tight.

    Beim Einwachsen von Gewebe in die radiale Tasche 10 verkeilt sich das Gewebe in der radialen Tasche 10 und sorgt für eine formschlüssige Verbindung Gewebe und der Oberfläche der radialen Tasche 10.When tissue grows into the radial pocket 10 the tissue is wedged in the radial pocket 10 and ensures a positive connection between the fabric and the Radial pocket surface 10.

    Der Verankerungsteller 13 ist radial um den Verankerungsteil 16 des hohlzylindrischen Schafts 14 angeordnet. Der Verankerungsteller 13 weist eine zur Hautoberfläche peripher abfallende Form auf, welche an einen Teller erinnert. Die abfallende Form bewirkt, dass sich die Haut bei Einwirkung eines Kippmoments auf den Portkörper 1 über den Verankerungsteller 13 rollt und nicht von dessen Rand 17 durchbohrt werden kann. The anchor plate 13 is radial around the Anchoring part 16 of the hollow cylindrical shaft 14 arranged. The anchor plate 13 has one Skin surface peripherally sloping shape, which on reminded a plate. The sloping shape causes the skin is affected by a tilting moment Port body 1 rolls over the anchor plate 13 and not from the edge 17 can be pierced.

    Im Verankerungsteller 13 sind Bohrungen 24 angelegt, welche vom umliegenden Gewebe durchwachsen werden und somit optimalen Halt bieten können.Bores 24 are made in the anchoring plate 13, which be overgrown by the surrounding tissue and thus can offer optimal support.

    Damit der Portdeckel 22 im implantierten Zustand geöffnet werden kann, ist am oberen Ende der Aussenfläche des Portschafts 15 eine Montagehilfsaussparung 9 angeordnet. Drei solche Aussparungen 9 auf gleicher Höhe werden von einem Spezialwerkzeug gefasst und der Deckel 22, dessen Öffnung 31b sechskantig ausgeführt ist, wird durch eine Drehbewegung aus der Verbindung mit dem Portkörper 14 gelöst.So that the port cover 22 is opened in the implanted state is at the upper end of the outer surface of the Porschafts 15 an auxiliary mounting recess 9 is arranged. Three such recesses 9 are at the same level a special tool and the cover 22, the Opening 31b is hexagonal, is through a Rotational movement from the connection with the port body 14 solved.

    Bei einem percutanen Portkörper 1, wird der Deckel 22 vorzugsweise in einer hautähnliche Farbe hergestellt, da diese Fläche gegen aussen sichtbar ist. Selbstverständlich kann auch der ganze Portkörper in einer hautähnlichen Farbe hergestellt werden.In the case of a percutaneous port body 1, the cover 22 preferably made in a skin-like color because this surface is visible to the outside. Of course the whole port body can also have a skin-like color getting produced.

    Claims (10)

    Implantierbare zylinderförmige Vorrichtung (1) für die Verbindung eines Schlauches ausserhalb des menschlichen oder tierischen Körpers mit einem innerhalb dieses Körpers gelegenen Schlauches (2), dadurch gekennzeichnet, dass um die zylinderförmige Vorrichtung (1) eine zur Hautoberfläche peripher abfallende Verankerungsplatte (13) angeordnet ist.Implantable cylindrical device (1) for the Connection of a hose outside the human or animal body with one inside that body located hose (2), characterized in that um the cylindrical device (1) one to the skin surface peripherally falling anchor plate (13) is arranged. Vorrichtung nach Anspruch 1, dadurch gekennzeichnet, dass vom Aussenmantel der zylindrischen Vorrichtung (1) eine oder mehrere radiale Rippen (11) abstehen.Device according to claim 1, characterized in that from the outer jacket of the cylindrical device (1) protrude one or more radial ribs (11). Vorrichtung nach Anspruch 1, dadurch gekennzeichnet, dass von der Verankerungsplatte (13) eine oder mehrere Rippen (12) abstehen.Device according to claim 1, characterized in that of the anchoring plate (13) one or more Stand out ribs (12). Vorrichtung nach einem der Ansprüche 1 bis 3, dadurch gekennzeichnet, dass der Abstand der beiden Rippenränder (lla,12a) geringer ist, als der Querschnittdurchmesser der durch die Rippen (11,12) gebildeten kanalförmigen radialen Tasche (10).Device according to one of claims 1 to 3, characterized characterized that the distance between the two rib edges (lla, 12a) is smaller than the cross-sectional diameter of the through the ribs (11,12) formed channel-shaped radial Bag (10). Vorrichtung nach einem der Ansprüche 1-4, dadurch gekennzeichnet, dass die Vorrichtung aus einem Kunststoffteil gespritzt werden kann. Device according to one of claims 1-4, characterized characterized in that the device consists of a Plastic part can be injected. Vorrichtung nach einem der Ansprüche 1 bis 5, dadurch gekennzeichnet, dass die Vorrichtung (1) oder Teile davon eine hautähnliche Farbe haben.Device according to one of claims 1 to 5, characterized characterized in that the device (1) or parts thereof have a skin-like color. Vorrichtung nach einem der Ansprüche 1 bis 6, dadurch gekennzeichnet, dass die Vorrichtung (1) vollkommen unter der Haut angeordnet ist.Device according to one of claims 1 to 6, characterized characterized in that the device (1) completely under the skin is arranged. Vorrichtung nach einem der Ansprüche 1 bis 6, dadurch gekennzeichnet, dass eine Fläche, welche mit einer Öffnung (31b) versehen ist, nicht innerhalb des Körpers angeordnet ist.Device according to one of claims 1 to 6, characterized characterized that an area with an opening (31b) is not arranged inside the body is. Vorrichtung nach einem der Ansprüche 1 bis 8, dadurch gekennzeichnet, dass der innerhalb des menschlichen oder tierischen Körpers gelegene Schlauch eine Öffnung (32) der Vorrichtung abdichtet und ein Deckel (22), in dessen Zentrum sich eine kleinere Öffnung (31b) befindet, eine zweite Öffnung (31a) der Vorrichtung verkleinert.Device according to one of claims 1 to 8, characterized characterized that of within human or animal body hose an opening (32) of the Seals device and a cover (22), in the There is a smaller opening (31b) in the center, one second opening (31a) of the device is reduced. Vorrichtung nach einem der Ansprüche 1 bis 9, dadurch gekennzeichnet, dass im Inneren der Vorrichtung (1) eine durchstossbare, elastische Membran (21) angeordnet ist, welche die zweite Öffnung (31b) abdichtet.Device according to one of claims 1 to 9, characterized characterized in that inside the device (1) penetrable, elastic membrane (21) is arranged, which seals the second opening (31b).
    EP98810214A 1997-03-26 1998-03-13 Implantable drug delivery device Expired - Lifetime EP0867197B1 (en)

    Applications Claiming Priority (3)

    Application Number Priority Date Filing Date Title
    CH00729/97A CH692239A5 (en) 1997-03-26 1997-03-26 Port body for drug administration.
    CH72997 1997-03-26
    CH729/97 1997-03-26

    Publications (3)

    Publication Number Publication Date
    EP0867197A2 true EP0867197A2 (en) 1998-09-30
    EP0867197A3 EP0867197A3 (en) 1998-12-23
    EP0867197B1 EP0867197B1 (en) 2003-10-01

    Family

    ID=4193827

    Family Applications (1)

    Application Number Title Priority Date Filing Date
    EP98810214A Expired - Lifetime EP0867197B1 (en) 1997-03-26 1998-03-13 Implantable drug delivery device

    Country Status (9)

    Country Link
    US (1) US6270475B1 (en)
    EP (1) EP0867197B1 (en)
    JP (1) JP4030179B2 (en)
    AT (1) ATE250955T1 (en)
    AU (1) AU726768B2 (en)
    CA (1) CA2233043C (en)
    CH (1) CH692239A5 (en)
    DE (1) DE59809760D1 (en)
    ZA (1) ZA982512B (en)

    Cited By (7)

    * Cited by examiner, † Cited by third party
    Publication number Priority date Publication date Assignee Title
    WO2003020343A1 (en) 2001-08-31 2003-03-13 Disetronic Licensing Ag Connecting device for a percutaneously implanted port and port system comprising the connecting device
    WO2003020360A1 (en) 2001-08-31 2003-03-13 Disetronic Licensing Ag Membrane, membrane/cannula combination and connecting device
    WO2005056079A1 (en) * 2003-12-08 2005-06-23 Otto Bock Healthcare Gmbh Implant with a skin penetration section
    DE10142637B4 (en) * 2001-08-31 2009-07-09 Disetronic Licensing Ag Transcutaneous implant with surface structure and method for producing such an implant
    EP2616135A1 (en) * 2010-09-17 2013-07-24 Couch, Christopher John Conical port
    EP3760273A1 (en) 2019-07-02 2021-01-06 SeraIP AG Implantable skin penetration device
    WO2022148537A1 (en) 2021-01-06 2022-07-14 Securecell Ag Implantable skin-piercing device

    Families Citing this family (25)

    * Cited by examiner, † Cited by third party
    Publication number Priority date Publication date Assignee Title
    US20010051794A1 (en) * 1997-03-26 2001-12-13 Gilberto Bestetti Port body for the administration of drugs
    US6945955B1 (en) 1998-05-20 2005-09-20 Disetronic Licensing Ag Sensor system including a port body
    DE19822711B4 (en) * 1998-05-20 2006-11-23 Disetronic Licensing Ag Sensor system with port body
    US7864758B1 (en) * 2001-09-28 2011-01-04 Emc Corporation Virtualization in a storage system
    US7232429B2 (en) * 2002-04-08 2007-06-19 Boston Scientific Corporation Medical devices
    US7570997B2 (en) 2003-04-11 2009-08-04 Cardiac Pacemakers, Inc. Subcutaneous cardiac rhythm management with asystole prevention therapy
    US7302294B2 (en) 2003-04-11 2007-11-27 Cardiac Pacemakers, Inc. Subcutaneous cardiac sensing and stimulation system employing blood sensor
    US7979122B2 (en) 2003-04-11 2011-07-12 Cardiac Pacemakers, Inc. Implantable sudden cardiac death prevention device with reduced programmable feature set
    US20050240155A1 (en) * 2004-04-27 2005-10-27 Conlon Sean P Surgically implantable injection port having a centered catheter connection tube
    EP2471573B1 (en) 2008-04-17 2015-09-30 Apollo Endosurgery, Inc. Implantable access port device and attachment system
    US9023063B2 (en) 2008-04-17 2015-05-05 Apollo Endosurgery, Inc. Implantable access port device having a safety cap
    US8708979B2 (en) 2009-08-26 2014-04-29 Apollo Endosurgery, Inc. Implantable coupling device
    US8506532B2 (en) 2009-08-26 2013-08-13 Allergan, Inc. System including access port and applicator tool
    US8715158B2 (en) 2009-08-26 2014-05-06 Apollo Endosurgery, Inc. Implantable bottom exit port
    US8882728B2 (en) 2010-02-10 2014-11-11 Apollo Endosurgery, Inc. Implantable injection port
    US8992415B2 (en) 2010-04-30 2015-03-31 Apollo Endosurgery, Inc. Implantable device to protect tubing from puncture
    US20110270025A1 (en) 2010-04-30 2011-11-03 Allergan, Inc. Remotely powered remotely adjustable gastric band system
    US20110270021A1 (en) 2010-04-30 2011-11-03 Allergan, Inc. Electronically enhanced access port for a fluid filled implant
    US20120041258A1 (en) 2010-08-16 2012-02-16 Allergan, Inc. Implantable access port system
    US20120065460A1 (en) 2010-09-14 2012-03-15 Greg Nitka Implantable access port system
    US8821373B2 (en) 2011-05-10 2014-09-02 Apollo Endosurgery, Inc. Directionless (orientation independent) needle injection port
    US8801597B2 (en) 2011-08-25 2014-08-12 Apollo Endosurgery, Inc. Implantable access port with mesh attachment rivets
    US9199069B2 (en) 2011-10-20 2015-12-01 Apollo Endosurgery, Inc. Implantable injection port
    US8858421B2 (en) 2011-11-15 2014-10-14 Apollo Endosurgery, Inc. Interior needle stick guard stems for tubes
    US9089395B2 (en) 2011-11-16 2015-07-28 Appolo Endosurgery, Inc. Pre-loaded septum for use with an access port

    Citations (2)

    * Cited by examiner, † Cited by third party
    Publication number Priority date Publication date Assignee Title
    EP0302076B1 (en) 1986-04-18 1992-12-23 LUNDGREN, Dan Implant passageway
    US5306255A (en) 1991-09-07 1994-04-26 Hans Haindl Portcatheter

    Family Cites Families (11)

    * Cited by examiner, † Cited by third party
    Publication number Priority date Publication date Assignee Title
    US3783868A (en) * 1971-05-06 1974-01-08 Gulf Oil Corp Percutaneous implant
    US4183357A (en) * 1976-08-02 1980-01-15 Bentley Laboratories, Inc. Chronic transcutaneous implant assembly for enterostomies
    US4092983A (en) * 1977-01-31 1978-06-06 General Atomic Company Blood access device
    GB2050175B (en) * 1977-07-07 1982-07-14 Bentley Lab A traumatic valving mechanism
    US4321914A (en) * 1980-04-22 1982-03-30 W. L. Gore & Associates, Inc. Percutaneous conduit having PTFE skirt
    US4578063A (en) * 1984-09-14 1986-03-25 W. L. Gore & Assoc., Inc. Central venous catheter
    DE3742263A1 (en) 1987-12-12 1989-06-22 Plastik Fuer Die Medizin Pfm METHOD AND DEVICE FOR PERMANENTLY TAKING BLOOD FROM ANIMALS
    SE465910B (en) * 1988-01-28 1991-11-18 Jan Axel Svensson DEVICE FOR CONNECTING CATHETRES IN A SKIN REVIEW
    US4955861A (en) 1988-04-21 1990-09-11 Therex Corp. Dual access infusion and monitoring system
    US5242415A (en) * 1992-08-14 1993-09-07 L-Vad Technology, Inc. Percutaneous access device
    US5741234A (en) * 1996-07-16 1998-04-21 Aboul-Hosn; Walid Nagib Anatomical cavity access sealing condit

    Patent Citations (2)

    * Cited by examiner, † Cited by third party
    Publication number Priority date Publication date Assignee Title
    EP0302076B1 (en) 1986-04-18 1992-12-23 LUNDGREN, Dan Implant passageway
    US5306255A (en) 1991-09-07 1994-04-26 Hans Haindl Portcatheter

    Cited By (8)

    * Cited by examiner, † Cited by third party
    Publication number Priority date Publication date Assignee Title
    WO2003020343A1 (en) 2001-08-31 2003-03-13 Disetronic Licensing Ag Connecting device for a percutaneously implanted port and port system comprising the connecting device
    WO2003020360A1 (en) 2001-08-31 2003-03-13 Disetronic Licensing Ag Membrane, membrane/cannula combination and connecting device
    DE10142637B4 (en) * 2001-08-31 2009-07-09 Disetronic Licensing Ag Transcutaneous implant with surface structure and method for producing such an implant
    WO2005056079A1 (en) * 2003-12-08 2005-06-23 Otto Bock Healthcare Gmbh Implant with a skin penetration section
    EP2616135A1 (en) * 2010-09-17 2013-07-24 Couch, Christopher John Conical port
    EP2616135A4 (en) * 2010-09-17 2014-07-23 Couch Christopher John Conical port
    EP3760273A1 (en) 2019-07-02 2021-01-06 SeraIP AG Implantable skin penetration device
    WO2022148537A1 (en) 2021-01-06 2022-07-14 Securecell Ag Implantable skin-piercing device

    Also Published As

    Publication number Publication date
    EP0867197B1 (en) 2003-10-01
    AU5953398A (en) 1998-10-01
    AU726768B2 (en) 2000-11-23
    EP0867197A3 (en) 1998-12-23
    ZA982512B (en) 1998-09-30
    CA2233043A1 (en) 1998-09-26
    JPH10290840A (en) 1998-11-04
    US6270475B1 (en) 2001-08-07
    ATE250955T1 (en) 2003-10-15
    CA2233043C (en) 2007-09-18
    CH692239A5 (en) 2002-04-15
    JP4030179B2 (en) 2008-01-09
    DE59809760D1 (en) 2003-11-06

    Similar Documents

    Publication Publication Date Title
    EP0867197B1 (en) Implantable drug delivery device
    EP0582163B1 (en) Implantable device
    DE60112550T2 (en) IMPLANTABLE DEVICE FOR MEDICINAL INJECTION
    DE4335099C2 (en) Device for restricting percutaneous access to a septum
    DE69828281T2 (en) SUBCUTANEOUSLY INFUSION DEVICE
    EP0347743B1 (en) Septum for implantable devices releasing agents
    EP0587624B1 (en) Device for reliably filling the containers of an infusion pump
    DE60208933T2 (en) NEEDLE SAFETY DEVICE
    DE60004082T2 (en) READY TO USE CONNECTION DEVICE
    DE60106261T2 (en) DISTRIBUTION DEVICE WITH MICRONED PINS FOR THE TRANSDERMAL ADMINISTRATION OF A SUBSTANCE
    DE69233329T2 (en) Method for fluid transfer
    EP0867198B1 (en) Coupling system for medical applications
    DE69827328T2 (en) Pre-assembled syringe
    DE60309487T2 (en) FLOW RESTRICTOR WITH SAFETY FEATURES
    DE19745654A1 (en) Port for subcutaneous infusion
    EP0412191A1 (en) Implantable infusion device
    DE10125261A1 (en) Drug pump with sewing loop that is flush with the outer surface
    EP0289496A1 (en) Multi-path valve for a device for producing or administering infusion solutions
    WO2003018092A1 (en) Fastening device for injection needles
    EP2678054A1 (en) Syringe head, ejector unit, and syringe formed from same
    DE4402380A1 (en) Implantable dosing system
    DE2844206A1 (en) Protective cap for vessel mouth - has disc containing perforation point below removable section of end wall formed integral with cylindrical part of cap housing
    DE3503320A1 (en) Multi-way valve
    US20010051794A1 (en) Port body for the administration of drugs
    DE1137833B (en) Hypodermic injection syringe

    Legal Events

    Date Code Title Description
    PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

    Free format text: ORIGINAL CODE: 0009012

    AK Designated contracting states

    Kind code of ref document: A2

    Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

    AX Request for extension of the european patent

    Free format text: AL;LT;LV;MK;RO;SI

    PUAL Search report despatched

    Free format text: ORIGINAL CODE: 0009013

    AK Designated contracting states

    Kind code of ref document: A3

    Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT

    AX Request for extension of the european patent

    Free format text: AL;LT;LV;MK;RO;SI

    17P Request for examination filed

    Effective date: 19990623

    AKX Designation fees paid

    Free format text: AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

    17Q First examination report despatched

    Effective date: 20020419

    GRAH Despatch of communication of intention to grant a patent

    Free format text: ORIGINAL CODE: EPIDOS IGRA

    GRAS Grant fee paid

    Free format text: ORIGINAL CODE: EPIDOSNIGR3

    GRAA (expected) grant

    Free format text: ORIGINAL CODE: 0009210

    AK Designated contracting states

    Kind code of ref document: B1

    Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

    PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

    Ref country code: IE

    Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

    Effective date: 20031001

    Ref country code: FI

    Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

    Effective date: 20031001

    Ref country code: ES

    Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

    Effective date: 20031001

    REG Reference to a national code

    Ref country code: GB

    Ref legal event code: FG4D

    Free format text: NOT ENGLISH

    REG Reference to a national code

    Ref country code: CH

    Ref legal event code: EP

    REG Reference to a national code

    Ref country code: IE

    Ref legal event code: FG4D

    Free format text: GERMAN

    REF Corresponds to:

    Ref document number: 59809760

    Country of ref document: DE

    Date of ref document: 20031106

    Kind code of ref document: P

    PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

    Ref country code: GR

    Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

    Effective date: 20040101

    Ref country code: DK

    Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

    Effective date: 20040101

    REG Reference to a national code

    Ref country code: SE

    Ref legal event code: TRGR

    GBT Gb: translation of ep patent filed (gb section 77(6)(a)/1977)

    Effective date: 20040122

    PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

    Ref country code: LU

    Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

    Effective date: 20040313

    Ref country code: AT

    Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

    Effective date: 20040313

    PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

    Ref country code: MC

    Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

    Effective date: 20040331

    Ref country code: BE

    Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

    Effective date: 20040331

    REG Reference to a national code

    Ref country code: IE

    Ref legal event code: FD4D

    ET Fr: translation filed
    PLBE No opposition filed within time limit

    Free format text: ORIGINAL CODE: 0009261

    STAA Information on the status of an ep patent application or granted ep patent

    Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

    26N No opposition filed

    Effective date: 20040702

    BERE Be: lapsed

    Owner name: *DISETRONIC LICENSING A.G.

    Effective date: 20040331

    PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

    Ref country code: CH

    Payment date: 20070824

    Year of fee payment: 10

    PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

    Ref country code: PT

    Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

    Effective date: 20040301

    REG Reference to a national code

    Ref country code: CH

    Ref legal event code: PL

    PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

    Ref country code: LI

    Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

    Effective date: 20080331

    Ref country code: CH

    Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

    Effective date: 20080331

    PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

    Ref country code: IT

    Payment date: 20110326

    Year of fee payment: 14

    Ref country code: SE

    Payment date: 20110307

    Year of fee payment: 14

    REG Reference to a national code

    Ref country code: NL

    Ref legal event code: SD

    Effective date: 20120530

    REG Reference to a national code

    Ref country code: DE

    Ref legal event code: R082

    Ref document number: 59809760

    Country of ref document: DE

    Representative=s name: SCHWABE SANDMAIR MARX, DE

    REG Reference to a national code

    Ref country code: DE

    Ref legal event code: R082

    Ref document number: 59809760

    Country of ref document: DE

    Representative=s name: SCHWABE SANDMAIR MARX PATENTANWAELTE RECHTSANW, DE

    Effective date: 20120612

    Ref country code: DE

    Ref legal event code: R082

    Ref document number: 59809760

    Country of ref document: DE

    Representative=s name: SCHWABE SANDMAIR MARX, DE

    Effective date: 20120612

    Ref country code: DE

    Ref legal event code: R081

    Ref document number: 59809760

    Country of ref document: DE

    Owner name: ROCHE DIABETES CARE GMBH, DE

    Free format text: FORMER OWNER: DISETRONIC LICENSING AG, BURGDORF, CH

    Effective date: 20120612

    Ref country code: DE

    Ref legal event code: R081

    Ref document number: 59809760

    Country of ref document: DE

    Owner name: ROCHE DIAGNOSTICS GMBH, DE

    Free format text: FORMER OWNER: DISETRONIC LICENSING AG, BURGDORF, CH

    Effective date: 20120612

    REG Reference to a national code

    Ref country code: FR

    Ref legal event code: TP

    Owner name: F.HOFFMANN-LA ROCHE AG, CH

    Effective date: 20120702

    Ref country code: FR

    Ref legal event code: CA

    Effective date: 20120702

    Ref country code: FR

    Ref legal event code: TP

    Ref country code: FR

    Ref legal event code: CA

    REG Reference to a national code

    Ref country code: GB

    Ref legal event code: 732E

    Free format text: REGISTERED BETWEEN 20120726 AND 20120801

    REG Reference to a national code

    Ref country code: GB

    Ref legal event code: 732E

    Free format text: REGISTERED BETWEEN 20120809 AND 20120815

    REG Reference to a national code

    Ref country code: SE

    Ref legal event code: EUG

    PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

    Ref country code: SE

    Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

    Effective date: 20120314

    PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

    Ref country code: IT

    Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

    Effective date: 20120313

    REG Reference to a national code

    Ref country code: FR

    Ref legal event code: PLFP

    Year of fee payment: 18

    REG Reference to a national code

    Ref country code: FR

    Ref legal event code: PLFP

    Year of fee payment: 19

    REG Reference to a national code

    Ref country code: DE

    Ref legal event code: R082

    Ref document number: 59809760

    Country of ref document: DE

    Representative=s name: SCHWABE SANDMAIR MARX PATENTANWAELTE RECHTSANW, DE

    Ref country code: DE

    Ref legal event code: R082

    Ref document number: 59809760

    Country of ref document: DE

    Representative=s name: SCHWABE SANDMAIR MARX, DE

    Ref country code: DE

    Ref legal event code: R081

    Ref document number: 59809760

    Country of ref document: DE

    Owner name: ROCHE DIABETES CARE GMBH, DE

    Free format text: FORMER OWNER: ROCHE DIAGNOSTICS GMBH, 68305 MANNHEIM, DE

    PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

    Ref country code: NL

    Payment date: 20160307

    Year of fee payment: 19

    PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

    Ref country code: FR

    Payment date: 20160223

    Year of fee payment: 19

    Ref country code: GB

    Payment date: 20160224

    Year of fee payment: 19

    PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

    Ref country code: DE

    Payment date: 20160324

    Year of fee payment: 19

    REG Reference to a national code

    Ref country code: DE

    Ref legal event code: R119

    Ref document number: 59809760

    Country of ref document: DE

    REG Reference to a national code

    Ref country code: NL

    Ref legal event code: MM

    Effective date: 20170401

    GBPC Gb: european patent ceased through non-payment of renewal fee

    Effective date: 20170313

    REG Reference to a national code

    Ref country code: FR

    Ref legal event code: ST

    Effective date: 20171130

    PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

    Ref country code: NL

    Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

    Effective date: 20170401

    Ref country code: FR

    Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

    Effective date: 20170331

    Ref country code: DE

    Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

    Effective date: 20171003

    PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

    Ref country code: GB

    Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

    Effective date: 20170313